Acrivon Therapeutics Inc....

NASDAQ: ACRV · Real-Time Price · USD
1.38
-0.01 (-0.72%)
At close: Aug 15, 2025, 12:15 PM

Acrivon Therapeutics Common Stock Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
1.01M 536K 1.09M 832K
Gross Profit
-1.01M -536K -1.09M -832K
Operating Income
-89.2M -67.24M -33.19M -16.18M
Interest Income
9.2M n/a n/a n/a
Pretax Income
-80.56M -60.39M -31.17M -16.24M
Net Income
-80.56M -60.39M -31.17M -16.24M
Selling & General & Admin
25.21M 21.21M 8.71M 2.47M
Research & Development
63.99M 45.49M 23.95M 13.72M
Other Expenses
-1.01M n/a n/a n/a
Operating Expenses
88.19M 66.7M 32.66M 16.18M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a 134K n/a n/a
Cost & Expenses
89.2M 67.24M 33.19M 16.48M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
337.92M 22.08M 21.92M 20.86M
Shares Outstanding (Diluted)
337.92M 22.08M 21.92M 20.86M
EPS (Basic)
-0.24 -2.74 -1.42 -0.78
EPS (Diluted)
-0.24 -2.74 -1.42 -0.78
EBITDA
-79.55M -59.85M -30.07M -15.41M
EBIT
-80.56M -60.39M -31.17M -16.24M
Depreciation & Amortization
1.01M 536K 1.09M 832K